Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LFCR
Lifecore Biomedical, Inc. (LFCR) EV/Sales
As of 16 October 2026, Lifecore Biomedical, Inc. (LFCR) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from −6.4× (February 2022) to 68.9× (August 2021); the current reading is higher than 77% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.0× | 19.41% |
| FY2024 | 2.5× | (34.53%) |
| FY2023 | 3.8× | (0.90%) |
| FY2022 | 3.8× | (27.45%) |
| FY2021 | 5.3× | 67.35% |
| FY2020 | 3.2× | 310.72% |
| FY2019 | 0.8× | (11.94%) |
| FY2018 | 0.9× | (4.58%) |
| FY2017 | 0.9× | 19.91% |
| FY2016 | 0.8× | (0.70%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.1× | 39.53% |
| Mar 2026 | 2.2× | (34.48%) |
| Sep 2025 | 3.3× | 2.32% |
| Aug 2025 | 3.3× | (2.32%) |
| 44 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −9.7× |
| AKBA Akebia Therapeutics, Inc. compare | 0.3× |
| ACB Aurora Cannabis Inc. compare | 0.9× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| ANIK Anika Therapeutics Inc. compare | 2.1× |
| LFCR Lifecore Biomedical, Inc. | 3.4× |
| SIGA Siga Technologies Inc. compare | 5.0× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)